Katrine B Melhus Selected Research

thorium-227-DOTA-rituximab

11/2009

In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katrine B Melhus Research Topics

Disease

4	Lymphoma (Lymphomas) 11/2009 - 02/2006
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2013 - 02/2006
2	Neoplasms (Cancer) 01/2013 - 09/2007
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2013

Drug/Important Bio-Agent (IBA)

4	Immunoconjugates (Immunoconjugate)IBA 01/2013 - 02/2006
3	Rituximab (Mabthera)FDA Link 01/2013 - 08/2007
2	AntigensIBA 01/2013 - 02/2006
1	EpitopesIBA 01/2013
1	Monoclonal AntibodiesIBA 01/2013
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 11/2009
1	AcidsIBA 11/2009
1	thorium-227-DOTA-rituximabIBA 11/2009
1	Thorium-227IBA 09/2007
1	Radioisotopes (Radionuclides)IBA 09/2007

Therapy/Procedure

2	Therapeutics 01/2013 - 09/2007
2	Radioimmunotherapy 08/2007 - 02/2006